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Abstract
The importance of S100A4, a Ca2+-binding protein, in mediating tumour cell migration, both intracellularly and
extracellularly, is well documented. Tissue transglutaminase (TG2) a Ca2+-dependent protein crosslinking enzyme, has also
been shown to enhance cell migration. Here by using the well characterised non-metastatic rat mammary R37 cells
(transfected with empty vector) and highly metastatic KP1 cells (R37 cells transfected with S100A4), we demonstrate that
inhibition of TG2 either by TG2 inhibitors or transfection of cells with TG2 shRNA block S100A4-accelerated cell migration in
the KP1cells and in R37 cells treated with exogenous S100A4. Cell migration was also blocked by the treatment with the
non-cell permeabilizing TG2 inhibitor R294, in the human breast cancer cell line MDA-MB-231 (Clone 16, which has a high
level of TG2 expression). Inhibition was paralleled by a decrease in S100A4 polymer formation. In vitro co-
immunoprecipitation and Far Western blotting assays and cross-linking assays showed not only the direct interaction
between TG2 and S100A4, but also confirmed S100A4 as a substrate for TG2. Using specific functional blocking antibodies, a
targeting peptide and a recombinant protein as a competitive treatment, we revealed the involvement of syndecan-4 and
a5b1 integrin co-signalling pathways linked by activation of PKCa in this TG2 and S100A4-mediated cell migration. We
propose a mechanism for TG2-regulated S100A4-related mediated cell migration, which is dependent on TG2 crosslinking.
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Introduction
The onset of tumour metastasis is a complicated process
involving complex intracellular cell signalling network(s) elicited
via cell contact with the extracellular matrix (ECM), and also by
crosstalk between tumour cells, stromal cells and immune cells.
One important protein involved in this crosstalk is S100A4.
S100A4 is a member of the Ca2+-binding protein S100 family,
which has been widely found to be over-expressed in highly
metastastic cancers and characterized as a marker of tumour
progression [1,2]. S100A4 is reputed to act both in the
intracellular and extracellular environment. Intracellular S100A4
can bind directly to the myosin light chain to mediate cytoskeletal
organization and in turn promote cell migration [3]. Via its direct
interaction with NF-kB, S100A4 is also reputed to be involved in
cancer cell proliferation and differentiation [4]. However, S100A4
is also found in the extracellular environment, where it can be
externalised from cancer cells and surrounding stromal and
immune cells via an unknown non-coventional secretion pathway.
Extracellular S100A4, like the intracellular protein, can also
promote cell migration, but its mode of action is still not fully
undertsood. It has been suggested that RAGE [5] or a6b4 integrin
[6] could be the cell surface receptors involved in transducing the
S100A4-mediated signalling, while other research suggests the
involvement of cell surface heparan sulphates in the signal
transduction process [7].
Another important protein, which functions both in the intra-
and extracellular environment and which is linked to cancer
progression both in breast and other cancers, is the multifunctional
enzyme tissue transglutaminase (TG2) [8]. Like S100A4, TG2 is a
Ca2+-binding protein, which mediates a transamidating reaction
leading to protein crosslinking in a Ca2+-dependent manner [9]. In
the intracellular environment, its transamidation activity is tightly
regulated by the binding of GTP/GDP, but its activity is easily
detectable at the cell surface or in the extracellular matrix, where
activating levels of Ca2+ are available [9]. In adition, cell surface
TG2 may act extracellularly as a novel adhesion protein via it its
binding to fibronectin (FN) and association with b1 and b3
integrins [10] and with cell surface heparan sulphates [11–13]. It
has also been shown that, in breast cancer cells, TG2 may function
as a scaffold protein via its potential association with the actin
cytoskeleton [14]. Importantly in many cancer cells increased TG2
activity is associated with an increased malignant phenotype
including increased drug resistance, which can be reversed by
TG2 siRNA silencing [15]. Through an unknown secretion
pathway, TG2, like S100A4, is externalized onto the cell surface
and into the ECM, where like S100A4 it has been shown to bind
to cell surface heparan sulphates for which it has a high affinity
and which are thought necessary for translocation of the enzyme
into the ECM [12]. Cell surface heparan sulphates are also
required for maintaining its transamidation activity and the
function of TG2 as a cell adhesion protein [11,13]. We recently
reported that syndecan-4, a member of the heparan sulphate
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proteoglycan family, can via its binding to TG2 mediate a novel
RGD-independent cell adhesion mechanism involving activation
of PKCa and activation of a5b1 integrin. The inside-out signalling
mechanism which is elicited is also able to enhance the formation
and deposition of FN fibrils [16].
Even though there is no direct link between TG2 and S100A4-
mediated cell migration, it has been shown that TGs, including
TG2, can crosslink members of the S100 family, such as S100A7,
S100A10 and S100A11 [17]. Interestingly, the mutagenesis of the
C-terminus of S100A4, which is the target for TG2 crosslinking
prevents the enhanced migratory phenotype. Given this close link
between the S100A4 protein and TG2 and their ability to affect
cell cancer cell migration our objective in this paper was to explore
the potential involvement of TG2 in regulating S100A4-related
cell migration and to elucidate the mechanisms involved.
Materials and Methods
Reagents and Antibodies
Human plasma FN and recombinant human S100A4 were
from Sigma-Aldrich (UK) and R&D system (UK), respectively.
Purified guinea pig liver TG2 (gplTG) was purified according to
Leblanc et al [18]. Unit of enzyme activity is defined as the
formation of 1.0 mmol of hydroxamate per min from Na-Z-Gln-
Gly and hydroxylamine at pH 6.0 at 37uC. Vectashield mounting
medium was purchased from Vector Laboratories. Rat TG2
shRNAs and the control shRNA were purchased from Qiagen
(UK). The cell culture medium solutions and antibiotics were from
PAA (UK). Lipofectamine 2000 reagent and the OptiMEM
medium were from Invitrogen (UK). The site-directed irreversible
transglutaminase inhibitors 1,3-dimethyl-2 imidazolium derivative
R283 and the peptidic inhibitors R294 and R281 were synthesized
at Aston University, as previously described [19]. The TG2
specific inhibitor Z-DON (Z-DON-Val-Pro-Leu-OMe) was pur-
chased from Zedira (Germany). XTT reagents were from Roche
(UK).
The commercial antibodies used in this study are listed in
Table 1. The HRP-conjugated anti-mouse or rabbit secondary
antibodies were purchased from Sigma-Aldrich (UK) and Dako
(Denmark), respectively. Mouse monoclonal antibody 1D10 raised
against gplTG was manufactured in house.
Cell lines
The well characterised rat mammary cell lines [20] used in this
study were a king gift from Dr. Roger Barraclough (University of
Liverpool, UK) and consisted of a non-metastatic rat mammary
cells Rama37 stably transfected with either a Neo-Vector (R37) or
plasmid containing human S100A4 (KP1). Cells were selected by
using G418 to establish the stable cell lines. The cells were
maintained in complete DMEM medium containing G418 as
described previously [20]. The MDA-MB-231 (Clone 16), which
has high TG2 expression and shows increased migration and
increased resistance to doxorubicin, was a kind gift of Dr. Kapil
Mehta (University of Texas, USA). The MDA-MB-231 wild type
cell line was a kind gift from Dr. Stephane Gross (Aston
University, UK).
To knock down TG2 expression, R37 and KP1 cells were
transfected with the rat TG2 shRNA (#1–4) or the control
scrambled shRNA using Lipofectamine 2000 reagent following the
manufacture’s instruction and the transfected cells were selected
using puromycin (5 mg/ml) after 48 h transfection. The stable cell
lines were maintained in cell culture medium containing 2.5 mg/
ml puromycin.
Cleavage of the 66 his-tag from the recombinant
proteins
The cleavage of the 66 his-tag from the recombinant S100A4
protein was performed using the Enterokinase cleavage capture kit
(Novagen, UK) following the manufacture’s instruction. After
optimization, the rEK: target protein ratio at 1:50 was chosen to
remove the his-tags from the recombinant S100A4 at room
temperature for 16 h. The recombinant Enterokinase was
removed using the EKapture Agarose columns and the target
protein was recovered for future experiments.
In vitro crosslinking
In vitro crosslinking assays were performed as documented
previously [17]. Briefly, 1 mg of recombinant human S100A4
protein was incubated with gplTG (0.05-1U) in the presence of
10 mM CaCl2 for 1 h at 37uC in reaction buffer containing
50 mM Tris-HCl, pH 7.4, 1 mM EDTA, 3.4 mM DTT, 30 mM
NaCl, 0.1% Triton X-100. The reaction was terminated by
adding 20 mM EDTA and by incubating the samples on ice. SDS-
PAGE and Western blotting were used to detect the presence of
S100A4 polymers by using anti-S100A4 antibody.
Co-immunoprecipitation
Co-immunoprecipitation (co-IP) assays were performed follow-
ing incubation of 1 mg of recombinant human S100A4 and 1 mg of
gplTG at 37uC for 1 h. For the interaction between syndecan-4
and crosslinked S100A4, the in vitro crosslinking reaction was
performed as introduced above in the presence or absence of TG
inhibitor R283, followed by incubating the products with 1 mg of
recombinant human syndecan-4 at 37uC for 1 h. The co-IP assay
was performed by using the co-IP kit (Pierce, UK) according to the
manufacture’s instruction. Briefly resin beads were coated with the
relevant antibodies (i.e. anti-S100A4, anti-TG2 or anti-syndecan-4
antibody). The immunocomplexes were incubated with the beads,
then collected into Laemmli sample buffer and then boiled at
Table 1. List of antibodies used for IHC, IF and Western
blotting.
Antigen Species source Company
TG2 (Cub7402) Mouse, monoclonal Neomarkers (Thermo, UK)
TG2 (TG100) Mouse, monoclonal Neomarkers (Thermo, UK)
TG2 Rabbit, polyclonal Cell Signalling (NEB, UK)
S100A4 Mouse, monoclonal AbD Serotec (UK)
S100A4 Rabbit, polyclonal Dako (Denmark)
TG1 Rabbit, polyclonal Abcam (UK)
Syndecan-4 Rabbit, polyclonal Invitrogen (UK)
b1 Integrin Rabbit, polyclonal Santa Cruz (UK)
b4 Integrin Rabbit, polyclonal BD biosciences (UK)
a5 Integrin Rabbit, polyclonal Santa Cruz (Germany)
a6 Integrin Rabbit, polyclonal Cell Signalling (NEB, UK)
RAGE Rabbit, polyclonal Cell Signalling (NEB, UK)
PKCa Mouse, monoconal Santa Cruz (UK)
Caspase-3 Rabbit, polyclonal BD Biosciences (UK)
66His tag Mouse, monoconal Invitrogen (UK)
a-Tubulin Mouse, monoconal Sigma-Aldrich (UK)
doi:10.1371/journal.pone.0057017.t001
TG2 and S100A4 in Cell Migration
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100uC for 5 min. Western blotting was carried out by using
specific antibodies to detect the targetting antigen in the
immunocomplexes as introduced previously [16].
Far Western blotting
This assay was performed as documented previously [21].
S100A4 or TG2 was blotted onto Immobilon-P membranes.
Membranes were then blocked using 50 mM Tris-HCl, pH 7.5,
containing 0.2 M NaCl, 3% bovine serum albumin (BSA) and
0.1% polyethylene glycol 8,000 for 2 h at room temperature
(blocking buffer). 1 mg of the bait proteins (TG2 for S100A4
membranes and S100A4 for TG2 membranes) were then
incubated with the membranes for 20 min at room temperature
in the reaction buffer (blocking buffer plus 1 mM CaCl2). After
washing three times, Western blotting was performed to detect the
bait protein on the membrane.
Dot blotting
R37 and KP1 cell culture medium was collected and the dot
blotting and Western blotting for the presence of S100A4 was
performed as described previously [12].
Solid phase binding assay to study the interaction of
S100A4 with TG2
Recombinant human S100A4 (after removal of the his-tags, at
1 mg/ml in Na2CO3 solution, pH 9.6) was coated onto 96- well
plates at 4uC overnight. After washing three time with 50 mM
Tris-HCl, pH 7.4, the wells were blocked with 3% BSA in PBS,
pH 7.4, 2 mg/ml recombinant human syndecan-4 (with his-tag) in
50 mM Tris-HCl, pH 7.4, was incubated in the wells at 37uC for
1 h. The presence of syndecan-4 bound to the S100A4-coated
wells was detected by using anti-his-tag antibody and anti-mouse
secondary antibody. The signals were detected using OPD
substrate and the absorbance measured at 490 nm.
Figure 1. S100A4-transfection enhances cell migration in Rama 37 cells, which can be blocked by TG inhibitors. (A) The presence of
S100A4 in R37 and KP1 cells. The presence of S100A4 in R37 and KP1 cell lysates was detected via Western blotting, while the antigen in the cell
culture medium was detected by dot blotting. Extracellular S100A4 was detected by immunofluorescence using anti-human S100A4 antibody using
live cells and visualized using confocal microscope as described in the Materials and Methods. Bar, 25 mm. (B) Effect of S100A4 on cell migration.
1.256105 cells/well of R37 or KP1 cells cultured in complete medium containing 10% serum were seeded into 12-well plates and incubated for 48 h
to reach confluency. Wound areas were scratched by using 200 ml microtips and the cells then allowed to migrate for 16 h in 1.5% serum, thus
limiting cell proliferation. At least 3 images were taken from each wound to verify the closure rate of the wound and three separate experiments were
performed. The images represent one typical area of each group. (C) Cell proliferation rates of R37 and KP1 cells in 1.5% serum. R37 and KP1
cells in DMEM medium containing 1.5% serum were seeded into 96-well plates at the density of 3,000 cells/well. The XTT assay was performed at 0 h
and 16 h incubation time points as described in the Materials and Methods. Data represent the mean 6 S.D. from 3 separate experiments.
doi:10.1371/journal.pone.0057017.g001
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TG activity assay
The commercial TG2-CovTest (Covalab) specific for TG2
activity in cell lysates was performed according to the manufac-
ture’s instruction [22]. Briefly, the cell lysate containing 50 mg of
total protein was incubated with spermine pre-coated wells in the
presence of biotin-labelled TG2 specific T26 peptide, DTT and
Ca2+. The incorporated T26 peptide was detected by incubating
with HRP-conjugated Extr-avidin. The reaction was developed
using OPD substrates and measured at 450 nm by using a plate
reader.
Cell surface TG activity was measured by incubating live cells
(26104/well) with 0.1 mM biotin-cadaverine in serum free
medium on FN-coated wells at 37uC for 2 h. The reaction was
stopped with 2 mM EDTA in PBS, pH 7.4, and the cells were
removed by 0.1% (w/v) deoxycholate in 2 mM EDTA in PBS,
pH 7.4. The rest of the reaction was performed as described above
for cell lysates above using HRP-conjugated Extr-avidin.
Wound healing assay
R37 and KP1 cells were grown in complete medium containing
10% FBS in 12-well plates for 48 h to form a mono-cell layer
before the wound was scratched. The cells were allowed to migrate
in medium containing 1.5% serum (in order to limit any
interference on migration by cell proliferation) at 37uC for 16 h
in the presence of the different treatments. The cells were fixed
with 3.7% paraformaldehyde in PBS, pH 7.4 for 15 min and
permeabilized with 0.1% Triton in PBS, pH 7.4 for 15 min. May-
Graunward and Giemsa co-staining was performed as described
previously [23]. The images of the wound areas were taken by
using Nikon digital camera at620. At least 3 images were taken
from each wound and the closure of the wound areas was
calculated. R37 cells without the migratory ability were used as the
control group. The wound areas were measured using the ImageJ
software and the percentage closure of the wound areas presented
as mean 6 S.D. from 3 separate experiments.
Figure 2. Inhibitory effect of TG2 inhibitors on S100A4-related cell migration. (A) Wound healing assays were carried on as introduced in
Fig. 1. 0.5 mM of TG inhibitors, R281, R283, or 0.25 mM R294, 0.1 mM MDC or TG2-specific antibody Cub7402 (20 mg/ml) was added to the cell
culture medium containing 1.5% serum, thus limiting cell proliferation. Wound closure was followed over 16 h. After fixation and staining, the wound
areas of the KP1 cells were analysed (B) as described in the Materials and Methods. At least 3 separate experiments were performed per treatment.
The mean percentage wound closure mean 6 S.D. is shown in (B). *, p,0.05 between the groups as indicated in the figure. (C) The effect of TG
inhibitors on the S100A4-related cell migration in the cover slip migration assay. R37 and KP1 cells were seeded onto 8 mm FN-coated
glass cover slips placed onto FN coated 24-well plates and allowed to migrate for 1 h in serum free medium with or without TG inhibitor R283 or
R294. The migrated cells were counted after the staining of the cells as introduced in Materials and Methods. Values represent the Mean values6 S.D.
from two separate experiments undertaken in duplicate.
doi:10.1371/journal.pone.0057017.g002
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Fluorescence staining
For staining of the extracellular S100A4 and in situ active TG2
in KP1 cells, the cells were pre-incubated with 8 mM FITC-
cadaverine in the presence or absence of non cell-permeable TG2
inhibitor R294 in complete medium at 37uC for 6 h [24]. To
detect the extracellular S100A4, rabbit anti-human S100A4
antibody (1:100 dilution) was then added into the cells for another
2 h incubation at 37uC. After washing three times carefully with
PBS, pH 7.4, the cells were fixed with methanol at 220uC for
20 min. After washing three times with PBS, pH 7.4 and blocking
with 3% BSA in PBS, pH 7.4 (blocking buffer) for 30 min at room
temperature, the cells were incubated with TRITC-conjugated
anti-rabbit secondary antibody in blocking buffer (1:100 dilution)
at 37uC for 2 h.
For vinculin and active form of caspase-3 staining KP1 cells
were fixed with 3.7% paraformaldehyde in PBS, pH 7.4 and
permeabilized with 0.1% Triton in PBS, pH 7.4. Cells were then
incubated for 4 h with specific primary antibodies and FITC or
TRITC-conjugated secondary antibody (1:100 dilution in block-
ing buffer) for 2 h/incubation. For the actin cytoskeleton staining,
15 mg/ml FITC-phalloidin was used in blocking buffer for 2 h at
37uC.
Following staining, cells were mounted in Vectorshield moun-
tant medium and the fluorescence signal detected by fluorescence
microscopy.
Cell migration assay
Migration assays were undertaken as previously described [24].
R37 and KP1 cells were seeded onto 8 mm cover slips pre-coated
with 5 mg/ml FN in 50 mM Tris-HCl, pH 7.4 in 24 well plates
and incubated for 1 h in serum-free medium to obtain cell
monolayers. The cover slips were then removed and transferred
into new 24-well plates coated with 5 mg/ml FN and the migration
of cells from the cover slip monitored for 4 h in the presence or
absence of the TG inhibitors. The total cell number which
migrated from the cover slips into the wells was then counted.
Three experiments were performed for each assay.
Cell viability assay
The XTT assay was used to measure viable cell numbers as
described previously [25].
Figure 3. The effect of TG2 inhibitors on R37 and KP1 viability. (A) The effect of TG inhibitors on R37 and KP1 cells using the XTT
assay. R37 and KP1 cells in DMEM medium containing 1.5% serum were seeded into 96-well plates at the density of 3,000 cells/well in the presence
or absence of TG2 inhibitors, R281, R283 and R294. The XTT assay was performed after a 16 h incubation time point as described in the Materials and
Methods. Data represent the mean 6 S.D. from 3 separate experiments. (B) Caspase staining for apoptosis. The presence of active caspase-3 in
the R37 and KP1 cells treated with TG2 inhibitor R294 was detected using fluorescent staining (red) and visualized under a fluorescence microscope
as described in the Materials and Methods, while DAPI was used for the nuclei staining (blue). Bar, 25 mm. (C) Effect of TG2 inhibitors on R37 and
KP1 cell viability after 72 h. The TG2 inhibitors were introduced to R37 and KP1 cells at the concentrations described above and incubated upto
72 h. The XTT assays were performed to detect cell viability as introduced in (A).
doi:10.1371/journal.pone.0057017.g003
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Cytosol and membrane fractionation
The cytosol and membrane fractions of R37 cells, stably
transfected with control scrambled or #3 TG2 shRNA, were
isolated as described previously [23]. Briefly cells were treated with
exogenous S100A4 in the presence or absence of TG2 inhibitor
R294 for 16 h in cell culture medium containing 1.5% serum.
Following incubation, the cells were washed once with ice-cold
PBS, pH 7.4 and collected into pre-chilled homogenization buffer
containing 20 mM Tris–HCl, pH 7.4, 10 mM EGTA, 2 mM
EDTA, 1 mM NaF, 1 mM Na3VO4, 50 nM okadaic acid,
0.1 mM PMSF and 1% (v/v) protein inhibitor cocktail. The cells
were lysed by 4 cycles of freezing and thawing (one cycle includes
incubating in liquid nitrogen for 2 min and incubating in water
bath at 37uC for 7 min). The cell lysates were then pre-cleared at
1,3006g for 10 min. The supernatants were collected and
centrifuged at 100,0006g for 60 min to separate cytosolic
(supernatant) and membrane fractions. The membrane fractions
were further washed once with ice-cold PBS, pH 7.4. The cytosol
and membrane fractions of samples were Western Blotted for
PKCa as described above.
Statistics
Data were expressed as mean 6 S.D. In some cases, the data
shown is derived from one representative experiment (n.3)
undertaken. The comparisons between the data sets were
performed using Student’s t test (two-tailed distribution with equal
variance). Statistical significant difference between data sets is
defined in the text by p,0.05 (two-sided).
Results
S100A4-transfection enhances cell migration in Rama 37
cells, which can be blocked by TG inhibitors
The role of S100A4 in regulating cell migration has been widely
reported [1]. A well-reported cell line KP1 (Rama37 cells
transfected with S100A4) and its control cell line R37 (Rama37
cell transfected with the empty vector) were used in this study. The
cell lines were first characterized via detecting the presence of
S100A4 protein in whole cell lysates and cell culture medium via
Western blotting and dot blotting, respectively. Immunofluores-
cent staining was used to detect extracellular S100A4. This
confirmed that there was negligible S100A4 in the R37 cells, while
S100A4 protein was over-expressed in KP1 cells and was also
found to be present in the cell culture medium (Fig. 1A). In the
Figure 4. Identification of TG2 in R37 and KP1 cells. (A) The presence of TG2 and TG1 in R37 and KP1 cells. Whole cell lysates from R37
and KP1 cells were prepared as described in the Materials and Methods. Western blotting was used to detect the presence of TG2 and TG1 antigen by
using the specific monoclonal TG2 antibody Cub7402 and a polyclonal anti-TG2 antibody and a polyclonal antibody against TG1, while a-Tubulin was
used as the equal loading standard for densitometric analysis, as shown in the inset histogram (mean 6 S.D. from two separate experiments
undertaken in duplicate). (B) Detection of TG2 activity in R37 and KP1 cell lysates. A TG2-specific CovTest assay was performed using R37 and
KP1 cell lysates (50 mg protein) as described in the Material and Methods. Data represent mean values 6 S.D. from 3 separate experiments. (C) Cell
surface TG activity was undertaken with live cells (26104 cells/well). Cells were incubated with biotin-cadaverine in serum free medium for 2 h after
plating onto FN coated wells. HRP conjugated Extr-avidin was used to detect the biotin-labelled crosslinking products as described in the Materials
and Methods. Data represent mean values 6 S.D. from 3 separate experiments. *, p,0.05 compared to the control sample.
doi:10.1371/journal.pone.0057017.g004
TG2 and S100A4 in Cell Migration
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cell lysates of KP1 cells large non-reducible Mr polymers could be
detected. Using the wound healing assay, enhanced migratory
ability was shown in the S100A4 stably-transfected KP1 cells,
when compared to their vector transfected control R37 cells,
confirming the role of S100A4 in mediating cell migration
(Fig. 1B). This difference in migration was not due to differences
in the cell proliferation rates between these two cells as measured
when cultured in the same medium containing 1.5% serum, in
which no cell proliferation was observed (Fig. 1C). To ascertain
whether TG2 activity might also play a role in the migratory
ability of KP1 cells, comparable assays were performed in the
presence of different TG2 inhibitors. Inhibitors used were either
the site directed irreversible inhibitors R283 (cell-permeable) or
cell impermeable R281 [26] and R294 [19], the competitive
primary amine substrate monodansyl-cadaverine (MDC) and a
TG2-specific antibody Cub7402. None of the inhibitors used
showed any significant toxicity when used at comparable
concentrations to those selected for the wound healing assay
Fig. 1C. As shown in Fig. 2 A and B, all of the inhibitors
including MDC and Cub7402 significantly blocked cell migration
in KP1 cells. A similar inhibitory effect of TG inhibitors R283 and
R294 was also found in the cover slip migration assay which
follows the R37 and KP1 cells migrating from the glass cover slip
into the cell culture wells in the presence or absence of the
inhibitors R283 and R294 (Fig. 2C).
Non-toxic effect of TG2 inhibitors was found in R37 and
KP1 cells
To investigate if there is any toxicity of TG2 inhibitors on R37
and KP1 cells, the XTT assay was undertaken after 16 h
incubation with the inhibitors, the time period used for the wound
healing assay. As shown in Fig. 3A, there was no effect of the TG2
inhibitors on R37 and KP1 cell proliferation. For measurement of
apoptosis, the presence of caspase-3 in R37 and KP1 cells was
detected via immuno-fluorescence staining. No difference in the
fluorescent signal was found between the groups with or without
TG2 inhibitor R294 treatment (Fig. 3B). When the TG2 inhibitor
treatment was extended to 72 h, no effect of the inhibitors on
viable cell number was found using the XTT assay (Fig. 3C).
The presence of TG2 and its direct interaction with
S100A4 in R37 and KP1 cells
To confirm the presence of TG2 in R37 and KP1 cells, Western
blotting was performed to detect the antigen in these cells by using
both mouse monoclonal anti-TG2 antibody Cub7402 and a rabbit
polyclonal anti-TG2 antibody. Easily detectable amounts of TG2
antigen were present in the cell lysates of both R37 and KP1 cells,
although higher (approx. 20%) in the R37 cells (Fig. 4A). Also
small amounts of the other TG family member, TG1 normally
found in cultured epithelial cells could be detected via Western
blotting in both cell lines (Fig. 4A). The TG2-specific commercial
assay for TG2 activity (TG2-CovTest assay) demonstrated activity
Figure 5. Inhibition of KP1 cell migration by transfection with TG2 shRNA. (A) Knock down of TG2 in KP1 cells. Western blotting was
performed to detect the presence of TG2 in KP1 cells stably transfected with TG2 shRNA (#3), while the scrambled shRNA was used as the control
vector. (B)Wound healing assay. The scratch assay for cell migration was performed as described in Fig. 1B using TG2 shRNA or scrambled shRNA
transfected KP1 cells. (C) The wound areas of the cells was analysed as described in the Materials and Methods. *, p,0.05 compared to the scrambled
shRNA transfected KP1 cells.
doi:10.1371/journal.pone.0057017.g005
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in the cell lysates of both cells, although as found with Western
blots slightly greater in the R37 cells (Fig. 4B). Measurement of
cell surface activity by biotin-cadaverine incorporation into FN
confirmed the presence of cell surface TG2 activity in both cells,
but unlike cell lysate activity was found to be significantly greater
in the KP1 cells (Fig. 4C). Importantly, the TG specific inhibitor
R294 (which does not inhibit extracellular Factor XIIIa at the
concentration of 0.25 mM) and the TG2 specific inhibitor Z-
DON [27–29] reduced the cell surface TG activity in both cell
lines, suggesting that TG2 is the major cell surface source of the
TG activity.
Knock down of TG2 expression abolishes the migratory
capability in KP1 cells
TG2 shRNAs were used to knockdown the expression of TG2
in KP1 cells and stably transfected cell lines were generated by
puromycin selection. As shown in Fig. 5A, shRNA#3 showed the
best knockdown in TG2 expression and was used in wound
healing assays. No changes in the levels of syndecan-4 or a5 and
b1 integrin were present in the shRNA treated cells when
compared to their scrambled shRNA controls (Fig. S1). Down-
regulation of TG2 expression significantly reduced the migratory
ability of KP1 cells (Fig. 5B and C), confirming the effect of TG2
inhibition on the migratory ability of KP1 cells.
S100A4, a substrate of TG2, directly interacts with the
enzyme
To investigate whether there is any direct interaction between
TG2 and S100A4, a co-IP assay was performed by using purified
TG2 and recombinant S100A4. As shown in Fig. 6A, by using
either the specific anti-TG2 antibody Cub7402 or the anti-
S100A4 antibody for the pull down and Western blotting to detect
the targeted protein, the direct interaction between the two
proteins can be demonstrated. Further proof of their interaction
was obtained using Far Western blotting. By incubating TG2 or
S100A4 (bait proteins) with the transferred membrane bound prey
proteins (either S100A4 or TG2), the presence of the bait protein
after binding is detected via immunoblotting (Fig. 6B). An in vitro
crosslinking assay demonstrated that S100A4 is a substrate of TG2
resulting in the formation of high molecular weight polymers, that
are comparable to the polymers found in the KP1 cell lysate. The
formation of these crosslinked polymers could be blocked by either
the addition of the Ca2+ chelator EDTA or the TG2 inhibitor
R283 (Fig. 6C).
Figure 6. S100A4, as a substrate of TG2 also binds directly with TG2. (A) Co-immunoprecipitation assay to detect the interaction
between S100A4 and TG2. After incubating recombinant S100A4 and gplTG at 37uC for 1 h, co-IP was performed. Briefly, specific antibodies,
against S100A4 and TG2, respectively, were bound to the resin beads before incubation with the protein mixture to form the antibody-antigen (bait
protein, S100A4 or TG2) complex. Mouse IgG and rabbit IgG were used as the negative control antibody (negative CNTL ab) for anti-TG2 antibody
Cub7402 and rabbit anti-S100A4 antibody, respectively. Western blotting was carried out to detect the presence of prey proteins (TG2 and S100A4 in
this case) as described in the Materials and Methods. (B) The interaction between S100A4 and TG2 via Far Western blotting. PVDF
membranes bound with rhS100A4 or gplTG were prepared via Western blotting after SDS-PAGE. The membranes containing the prey protein (either
S100A4 or TG2) were incubated with their relevant bait protein (gplTG or rhS100A4, respectively) as introduced in Materials and Methods and
Western blotting was performed to detect the presence of the bait proteins by using their specific antibodies, i.e. Cub7402 and rabbit anti-S100A4
antibody, respectively. (C) In vitro cross-linking assay to show S100A4 is a TG2 substrate. Recombinant S100A4 (after cleavage of the his-tags)
and gplTG at the concentrations in mg shown were incubated in the presence of Ca2+ and DTT at 37uC. The TG2 inhibitor or the Ca2+ chelator EDTA
were used as the negative controls. The presence of S100A4 polymers was detected by using Western blotting as introduced in the Materials and
Methods.
doi:10.1371/journal.pone.0057017.g006
TG2 and S100A4 in Cell Migration
PLOS ONE | www.plosone.org 8 March 2013 | Volume 8 | Issue 3 | e57017
The effect of R294 on KP1 cell morphology
To detect any co-localization of cell surface TG2 and S100A4
protein in the KP1 cells, fluorescence staining for in situ active TG2
was performed using FITC-cadaverine incorporation together
with the immunofluorescent extracellular staining of the S100A4
antigen. Cells were incubated live (prior to fixing) in the presence
of the antibody to S100A4 in order to immunostain the
extracellular S100A4. This showed a close co-localization of the
S100A4 antigen with the incorporation of FITC-cadaverine,
which could be disrupted when the cell impermeable TG2
inhibitor R294 was added to the cell culture (Fig. 7A). Incubation
of the KP1 cells with R294 also resulted in a dispersion of focal
adhesion staining, when detected using vinculin (Fig. 7B). This
dispersion of focal adhesions was accompanied by a parallel
reduction in organisation of the actin cytoskeleton detected using
fluorescently labelled phalloidin (Fig. 7C).
Identification of the cell surface receptor(s) in regulating
TG2/S100A4-mediated cell migration
Cell surface receptor(s) that extracellular S100A4 and TG2 are
reputed to be associated with and in turn can regulate cell
migration were detected via Western blotting. Increased expres-
sion of both syndecan-4 and a5 integrin was detected in KP1 cells
when compared to R37 cells although present in both cells, while
no difference in expression of other receptors, including RAGE,
b1, a6 and b4 integrins, was found between R37 and KP1 cells
(Fig. 8A). Fig. 8B shows the different approaches used to
functionally block these cell surface receptors and the observed
effect on the migratory ability of KP1 cells. Addition of heparin
(which can compete with cell surface heparan sulphates for the
binding of TG2 or S100A4 protein) or heparinase (which digests
the cell surface heparan sulphate chains) to KP1 cells was found to
significantly block cell migration, suggesting the involvement of
cell surface heparan sulphates in this process. Importantly, by
adding recombinant syndecan-4 to KP1 cells to compete out the
effect of cell surface syndecan-4, it was shown that addition of this
Figure 7. The effect of TG2 inhibitor R294 on in situ cell surface TG2 activity, S100A4 localisation, actin cytoskeleton and focal
adhesions. (A) Co-localization of in situ TG activity and S100A4. In situ TG activity was detected via FITC-cadaverine incorporation, by
incubating KP1 cells with FITC-cadaverine with or without the TG2 inhibitor R294 (0.25 mM), while extracellular S100A4 was stained by incubating the
live cells with anti-S100A4 antibody as described in the Materials and Methods. Staining was visualized by confocal microscopy. Bar, 25 mm. (B) The
effect of TG2 inhibitor R294 on focal adhesion formation in KP1 cells. KP1 cells were incubated with or with TG2 inhibitor R294 (0.25 mM)
for 16 h and the presence of vinculin in the focal adhesions were detected via immuno-fluorescence staining by anti-vinculin antibody and a FITC-
conjugated secondary antibody. Confocal microscopy was used to visualize the fluorescent signals. Bar, 35 mm. (C) The effect of TG2 inhibitor
R294 on KP1 actin cytoskeleton formation. KP1 cells were incubated with or with TG2 inhibitor R294 (0.25 mM) for 16 h. Actin was stained
using FITC-labelled phalloidin and the cells were visualized by confocal microscopy as described in the Materials and Methods. Bar, 35 mm.
doi:10.1371/journal.pone.0057017.g007
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exogenous protein also significantly inhibited the migration of KP1
cells (Fig. 8B and C). This strongly suggests that the candidate cell
surface heparan sulphate is syndecan-4, which is also the major
syndecan found in focal adhesions In addition the a5b1 integrin
targeting A5-1 peptide which is important in TG2/syndecan-4
mediated cell adhesion [16] also significantly blocked the S100A4-
enhanced cell migration in KP1 cells (Fig. 8B and C).
S100A4 can function extracellularly and cell surface
S100A4 is crosslinked by TG2, both of which can be
blocked with TG2 inhibitors
Given the cell surface co-localization of TG2 activity and
S100A4, the ability of the non-cell permeable TG2 inhibitors
R281 and R294 to reduce this and in parallel inhibit KP1 cell
migration, our results suggest that the major action of TG2 on
S100A4 is likely to be through an extracellular mediated signalling
pathway involving the cell surface receptor syndecan-4. To test
this hypothesis, recombinant S100A4 protein was first used to
exogenously treat the control R37 cells. As shown in Fig. 9A and
B the addition of exogenous S100A4 promoted the migration of
R37 cells. To confirm that TG2 was also involved in this
exogenous S100A4 stimulated migration cells were incubated with
the TG2 inhibitor R294, which resulted in significant inhibition of
the S100A4 stimulated migration (Fig. 9A and B). Importantly
S100A4 crosslinked in vitro and then added back to the inhibited
R37 cells could partially compensate the effect of TG2 inhibitor
R294 (Fig. 9A and B). To further confirm that the effect of the
exogenously added S100A4 shares a similar signalling pathway to
that of the KP1 cells which over-express endogenous S100A4,
wound healing assays were performed. Following cell wounding,
heparinase, recombinant syndecan-4, A5-1 inhibiting peptide
against a5b1 integrins and PKCa inhibitor Go6976 were added
to the scratched cells resulting in significant inhibition of the
exogenously stimulated S100A4 migration (Fig. 9A and B). The
knock down of TG2 expression by shRNA (#3) in R37 cells
(Fig. 9C), which had no effect on the key receptors b1 and a5
integrin or Syndecan-4 when compared to their scrambled shRNA
controls (Fig. S1), also led to the failure of the cells to respond to
the exogenous S100A4 treatment in the wound healing assay
(Fig. 9D and E), confirming the involvement of TG2 in
extracellular S100A4-induced cell migration.
The involvement of PKCa and syndecan-4 in TG2 and
S100A4-related signalling
The functional link between the activation of PKCa and TG2/
S100A4 stimulated migration was studied by detecting the
translocation of activated PKCa from the cytosol fraction to the
membrane. As shown in Fig. 10A and B exogenous S100A4
treatment of R37 cells increased the presence of the PKCa in the
membrane fraction, which was inhibited by the cell impermeable
Figure 8. Identification of cell surface receptors in KP1 and R37 cells and their importance in KP1 cell migration. (A) Western blotting
was performed to detect the presence of cell surface receptors in R37 and KP1 cell lysates by using their specific antibodies as introduced in Materials
and Methods. a-Tubulin was used as the equal loading standard. (B) Wound healing assays were performed in KP1 cells treated with chondroitinase
(15 mU/ml), heparinase (15 mU/ml), 0.3 mg/ml heparin, exogenous recombinant human syndecan-4 (1 mg/ml) and a5b1 integrin-targetting peptide
A5-1 (5 mM) as described in the Materials and Methods. At least 3 separate experiments were performed per treatment. And the mean percentage
wound closure 6 S.D. shown in (C). *, p,0.05 between the groups as indicated in the figure.
doi:10.1371/journal.pone.0057017.g008
TG2 and S100A4 in Cell Migration
PLOS ONE | www.plosone.org 10 March 2013 | Volume 8 | Issue 3 | e57017
TG2 inhibitor R294. Importantly, reduced membrane PKCa was
also found in the TG2 shRNA-transfected R37 cells, which failed
to respond to the exogenous S100A4 treatment. To further
investigate the direct association between syndecan-4 and S100A4,
a solid phase binding assay was first performed, which showed the
binding of syndecan-4 to the immobilized S100A4 (Fig. 10C).
Another approach of in vitro co-IP was applied to confirm the
direct interaction between syndecan-4 and TG2 crosslinked
S100A4 by using in vitro crosslinked or non-crosslinked S100A4
incubated with syndecan-4. Western blotting was then used to
detect the presence of S100A4 in the syndecan-4-related immuno-
complex (Fig. 10D). A strong signal for S100A4 polymers was
found in the syndecan-4 immunocomplex pulled down by anti-
syndecan-4 antibody, while a lesser amount of S100A4 monomer
was found bound to the syndecan-4 protein.
The role of S100A4 in TG2-regulating breast cancer
migration
The human breast cancer cell line MDA-MB-231 was used to
extend our observation for the importance of both TG2 and
S100A4 proteins in R37 and KP1 cells to human cancer cells.
Higher TG2 expression was detected in the clone 16 cells, while
negligible TG2 was found in the wild type MDA-MB-231 cells
(Fig. 11A). In the wound healing assay, increased migration was
observed in the high TG2 expressing clone16 cells when compared
to the wild type MDA-MB-231 cells which contain very low levels
of TG2 (Fig. 11B). Importantly in addition to R294 the TG2
monoclonal antibodies Cub7402, TG100 and 1D10 and the
polyclonal antibody for S100A4 could block the migration of these
cells. As found with KP1 cells, this suggests the involvement of
extracellular TG2 and S100A4 in regulating MDA-MB-231 clone
16 cell migration (Fig. 11C). Western blotting for S100A4 antigen
in clone16 cells showed the presence of high-molecular weight
Figure 9. Exogenous S100A4 enhances cell migration in R37 cells, which can be blocked by TG inhibitors and agents that interfere
with syndecan-4 signalling. (A) The wound healing assay in R37 cells was carried out in the presence of extracellular recombinant S100A4 (exo-
S100A4,1 mg/ml) with or without TG2 inhibitor R294 (0.25 mM) or with TG2 crosslinked-S100A4 in (exo-X-S100A4) in the presence of R294. The
wound assay was also carried out in the presence of heparinase (15 mU/ml), exogenous recombinant human syndecan-4 (1 mg/ml), a5b1 integrin-
targetting peptide A5-1 (5 mM) and PKCa inhibitor Go6976 (5 mM) added in the presence of exogenous S100A4 as described in the Materials and
Methods. At least 3 images were taken from each wound to verify the closure rate of the wound and three separate experiments were performed. (B)
Shows the mean percentage wound closure mean 6 S.D. from 3 separate experiments. *, p,0.05 between the groups as indicated in the figure. (C)
Knocking down of TG2 in R37 cells. Western blotting was performed to detect TG2 in R37 stably transfected with TG2 shRNA #3 or the
scrambled shRNA control. (D) Wound healing assay was carried out on R37 cells transfected with scrambled or TG2 shRNA #3 in the presence of
exogenous S100A4 treatment and analysed (E) As described in the Materials and Methods. *, p,0.05 between the groups as indicated in the figure.
doi:10.1371/journal.pone.0057017.g009
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S100A4 polymers, comparable to those found in the in vitro
crosslinking assay and in the KP1 cells, which could be reduced by
treatment of cells with the non-cell permeable TG2 inhibitor R294
(Fig. 11D).
Discussion
S100A4, acting as either an intracellular or extracellular
protein, can promote cell migration using a number of different
pathways, such as the activation of MMPs [30] through integrin
receptors [6] or through the RAGE signalling pathway [5], but the
exact mechanism is still not fully understood. Another protein
shown to promote cell migration is TG2, which can function
extracellularly via its binding to FN and heparan sulphate
proteoglycans. Over-expression of both proteins in cancer cells
has been linked to tumour progression [2]. In this paper we used
the well-characterised R37 cells [20] transfected with S100A4 to
assess whether the functions of TG2 and S100A4 are interrelated.
Investigation of TG2 activity in R37 control cells (transfected with
empty vector) and highly-metastatic KP1 cells (Rama cells
transfected with S100A4) indicated the presence of enzyme
activity in the cell lysates and on the cell surface. Interestingly,
the amount of TG2 found at the cell surface was greater in the
KP1 cells, even though the amount of TG2 protein found in the
cell lysates was slightly greater in the R37 cells. However, such a
redistribution of enzyme is not unusual under pathological
situations [31]. The first indication of a link between S100A4
and TG2 activity was obtained by treatment of the metastatic KP1
cells with specific site-directed irreversible inhibitors of TG2,
R281, R283 and R294, and the competitive primary amine
Figure 10. The involvement of syndecan-4/PKCa. (A) The activation of PKCa. The presence of PKCa in the cytosol and membrane fractions,
after exogenous S100A4 treatment of R37 cells transfected with scrambled or TG2 #3 shRNA, or R37 cells treated with R294 was detected using
Western blotting as introduced in the Materials and Methods. (B) Densitometry was performed to measure the Western blots from 3 separate
experiments and the ratio of membrane bound to cytosol PKCa plotted as a ratio after normalisation of the cytosol PKCa for protein loading *,
p,0.05 between exogenous S100A4 treated and the non-treated R37 cells transfected with the scrambled shRNA. (C) The direct interaction
between syndecan-4 and S100A4 via co-IP. Recombinant human S100A4 (after cleavage of the his-tags) was crosslinked by TG2 as introduced
in Materials and Methods. The crosslinked S100A4 was incubated with recombinant syndecan-4 at 37uC for 1 h and co-IP was performed using anti-
syndecan-4 antibody and Western blotting was performed to detect the presence of S100A4 as described in the Materials and Methods. The non-
crosslinked S100A4, namely the S100A4 protein incubated with inactive TG2 and syndecan-4 was used as the control group. (D) Solid binding
assay showing interaction between S100A4 and syndecan-4. The binding assay was performed to detect the interaction between S100A4
(pre-coated onto 96 well plates after cleavage of the his-tags) and recombinant human syndecan-4 as detailed in the Materials and Methods. The
coating buffer was used as the negative control coating. *, p,0.05 between the groups.
doi:10.1371/journal.pone.0057017.g010
TG2 and S100A4 in Cell Migration
PLOS ONE | www.plosone.org 12 March 2013 | Volume 8 | Issue 3 | e57017
substrate MDC, which were each able to block cell migration of
the S100A4 transfected KP1 cells. The finding that the cell
impermeable inhibitors, R281 and R294, inhibited cell migration
suggested that the involvement of TG2 in the migratory process is
likely to be at the cell surface in the KP1 cells. Moreover, the
inhibitory effect of MDC suggested that it is the transamidation
activity of TG2 that functions in S100A4-mediated cell migration,
instead of a conformation change, which can be induced by the
binding of site-directed irreversible TG2 inhibitors [32]. Impor-
tantly knockdown of the expression of TG2 in KP1 cells abolished
its migratory capability, further confirming the involvement of
TG2 in S100A4-related migration.
As a consequence of the finding that the extracellular S100A4
can enhance cell migration [33], our next step was to add S100A4
to the control R37 cells, which led to stimulation of migration and
which could be blocked by the cell impermeable TG2 inhibitor
R294. Migration could also be blocked by down-regulation of
TG2 expression by shRNA. Hence our data suggest that in these
cells both TG2 and S100A4 are acting extracellularly to stimulate
cell migration. In order to further study the relationship between
TG2 and S100A4 in regulating cell migration, a series of in vitro
studies were initially performed using pure proteins. Co-IP assays
revealed the direct interaction between these two proteins, while in
vitro cross-linking assays indicated that S100A4 could act as a TG2
substrate, as reported for other members of the S100A family [17].
TG2 (using FITC-cadaverine incorporation) and immunostaining
for the extracellular S100A4 antigen in KP1 cells indicated the
extracellular co-localization of the enzyme with the protein, which
could be inhibited by incubation of cells with the cell impermeable
TG2 inhibitor R294. Incubation of KP1 cells with R294 also
resulted in the disassembly of the punctuate cell surface staining of
S100A4 in these cells. Given the possibility that S100A4 is
associated with focal adhesions, it seems feasible that the parallel
disassembly of the actin cytoskeleton organization and focal
adhesions in the presence of the extracellular acting TG2 inhibitor
are interrelated. Importantly the assembly of focal adhesions and
the actin cytoskeleton is essential for cell migration. This data also
supports the role of S100A4 in regulating actin cytoskeleton re-
organization [1], however in this case the action on the actin
cytoskeleton seems to be mediated by an extracellular event which
involves TG2. The importance of S100A4 polymers in enhancing
cell migration has been well reported. It was therefore important
to show that add back of in vitro crosslinked S100A4 to TG2
inhibited R37 cells (i.e. the cells treated with TG2 inhibitors) could
Figure 11. The role S100A4 in TG2-related breast cancer cell migration. (A) The presence of TG2 in MDA-MB-231 cell lines. Western
blotting was performed to detect TG2 in MDA-MB-231 wild type and clone 16 cells. (B) Wound healing assays for clone 16 and wild type
MDA-MB-231 cells with or without treatment with TG2 inhibitor R294. (C) The importance of TG2 and S100A4 in MDA-MB-231
breast cancer cell migration. MDA-MB-231 wild type and clone 16 cells were used in the wound healing assay in the presence of TG2 antibodies
(Cub7402, TG100 and 1D10) and anti-S100A4 antibodies (rabbit polyclonal and mouse monoclonal) at the concentrations of 20 mg/ml, while TG2
inhibitor R294 was used at the concentration of 0.25 mM. Mouse control IgG and rabbit control IgG were used as the control treatments. At least 3
images were taken from each wound to analyse the closure rate of the wound and three separate experiments were performed. (D) S100A4 in
MDA-MB-231 clone 16 cells. Western blotting was performed to detect the presence of S100A4 antigen in clone 16 cells in the presence or
absence of TG2 inhibitor R294 by using specific anti-S100A4 antibody.
doi:10.1371/journal.pone.0057017.g011
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restore cell migration. The demonstration of this rescuing effect of
TG2 crosslinked S100A4 further confirmed that cell surface TG2
activity regulates extracellular related S100A4-mediated cell
migration via its crosslinking.
It has been shown that cell surface receptors, such as RAGE or
a6b4 integrin, are required by S100A4 to regulate cell migration
[1]. TG2, when bound to FN, can mediate cell adhesion either via
acting as a co-receptor for b1 and b3 integrins [10] or via
mechanism involving the direct binding to syndecan-4 and
activation of a5b1 via PKCa [23,34]. Interestingly recent reports
also indicated the importance of heparan sulphates in S100A4-
relevent cell migration [7]. To study the signalling pathway in
TG2-regulated cell migration by S100A4, Western blotting was
used to reveal any changes in cell surface receptors in the S100A4-
transfected cells, which revealed comparable receptor profiles
although slightly increased expression of syndecan-4, a5 integrins
in KP1 cells when compared to R37 control cells. No changes
were found in the expression of RAGE and a6b4 integrin. The
involvement of a5b1 integrin in the migratory mechanism of KP1
or S100A4-treated R37 cell was confirmed by the ability of the
a5b1 integrin-targeting peptide A5-1 [16] to inhibit cell migration
in the wound healing assay. The importance of cell surface
heparan sulphates in facilitating the S100A4-regulated cell
migration was demonstrated by the exogenous addition of
heparin, heparinase or recombinant syndecan-4 protein to cells,
which significantly slowed down cell migration. This strongly
suggests that syndecan-4 is the major heparan sulphate proteo-
glycans involved in S100A4 related migration. Moreover, disrup-
tion of both focal adhesion assembly by the TG2 inhibitor R294
and the parallel disruption of the punctate staining pattern of
S100A4 at the cell surface suggest that S100A4 is found associated
with syndecan-4 present in focal adhesions, thus explaining our
observations and link between the re-organization of focal
adhesions and TG2 inhibition.
Since syndecan-4 and a5b1 integrin mediate cell migration via
the activation of PKCa [23,34], it was not surprising to find that
both the PKCa inhibitor Go6976 and the GK21 peptide (which is
reported to block the direct interaction between intracellular
domain of b1 integrin and PKCa [23,35]) blocked the migration
of KP1 cells and S100A4-stimulated R37 cells. This suggests that
PKCa could be the important intracellular signalling link in TG2
and S100A4-mediated cell migration, since it has been shown that
PKCa is the signalling link between a5b1 integrin and syndecan-4
co-signalling [16,23]. By studying the translocation of PKCa from
cytosol to membrane, an indication of its activation, we showed
enhanced translocation of PKCa in the exogenous S100A4-
treated R37 cells, which was inhibited by TG2 inhibitor R294.
Importantly, R37 cells transfected with TG2 shRNA showed
lower levels of active PKCa and failed to respond to S100A4
treatment. This data provides the direct link between TG2 and
S100A4-related cell migration, which is through a syndecan-4/
a5b1 integrin co-signalling pathway linked by PKCa. A series of
further in vitro studies confirmed the direct interaction between
sydecan-4 and S100A4 as shown by using a solid binding assay
and co-IP. It is shown that there is a stronger binding between
crosslinked S100A4 polymers and syndecan-4, compared to the
non-crosslinked S100A4 monomer, further supporting our finding
that transamidation of S100A4 is a prerequisite to its biological
action, which is also confirmed by the ability of crosslinked
S100A4 to partially compensate the effect of TG2 inhibitor in R37
cell migration. Since S100A4 and TG2 are also thought to play an
important role in the progression of a number of human cancers
including breast cancer [2,36], it was important to test our theory
in a breast cancer cell system [37]. Hence for this study we used a
well-characterised breast cancer cell line MDA-MB-231 clone 16,
Figure 12. Diagram showing the potential role of TG2 in S100A4-regulated cell migration. The secretion of S100A4 from both tumour
stromal and tumour cells themselves can be cross-linked by cell surface/matrix TG2. Once crosslinked by TG2, S100A4 shows a high binding affinity
for heparan sulphate chains of syndecan-4 on the tumour cell surface and activates the syndecan-4 and inside out a5b1 integrin co-signalling
pathways via the intracellular signalling molecule PKCa, which accelerates tumour cell migration and metastasis.
doi:10.1371/journal.pone.0057017.g012
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which has been shown to have very high TG2 expression, is more
migratory and more resistant to doxorubicin, compared to its wild
type cell line [15]. These cells contain high molecular weight
immuno-reactive polymers of S100A4, which can be partially
decreased by treatment with the TG2 inhibitor R294. Interest-
ingly, the reduction of S100A4 polymer formation by R294 did
not restore the presence of the S100A4 monomer. The S100A4
monomer was also not detectable in the non-treated clone 16 cells.
A possible explanation for this is that the high TG2 levels in non-
treated clone 16 cells maintains the S100A4 protein in its
crosslinked form, thus preventing it from degradation and
prolonging its effect on regulating the metastastic phenotype. In
such a situation, the inhibition of polymer formation by R294
would also lead to the rapid degradation of any resulting non-
crosslinked S100A4 monomer, thus accounting for its absence
when polymer formation is partially inhibited. This protective
effect of protein crosslinking by transglutaminases is well
recognised and widely reported [38,39]. Importantly this reduc-
tion in S100A4 polymer content is paralleled by an inhibition of
cell migration in these cells when exposed to the TG2 inhibitor
R294 and to antibodies directed against either TG2 or S100A4.
Hence the involvement of TG2 with S100A4 in mediating the
increased migration found in a rat mammary cancer cell line may
also be extended to human breast cancer cells.
In conclusion, for the first time, our work demonstrates the
crucial link between two well-known important bio-markers for
highly metastastic cancers, namely TG2 and S100A4. We have
now shown that S100A4 is a substrate of TG2. That crosslinking
of S100A4 by TG2 can be inhibited by the TG2 specific inhibitor
R294, leading to the abolishment of S100A4-enhanced cell
migration. Importantly we demonstrate the mechanism for this
S100A4/TG2-related cell migration involving the activation of the
syndecan-4 and a5b1 integrin co-signalling pathway linked by
PKCa (Fig. 12). Our data reveal a novel potential strategy in
cancer therapy, which is to antagonize the link between TG2 and
S100A4 by inhibition of the crosslinking activity of TG2. By
discovering the mechanism in this signalling transduction path-
way, we propose that a combined treatment of TG2 inhibition
with the inhibition of key signalling targets e.g. PKCa could be
more promising therapeutic approach for the treatment of S100A4
and TG2 containing tumours.
Supporting Information
Figure S1 The presence of cell surface receptors in the shRNA
transfected R37 and KP1 cells. Western blotting was performed to
detect the presence of a5, b1 integrins and syndecan-4 in the TG2
shRNA #3 transfected R37 cells (A) or KP1 cells (B), while the
scrambled shRNA transfected cells were used as the control.
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